Loading
A phase 2 trial of pucotenlimab in colorectal cancer, run by Sun Yat-sen University, now recruiting.
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07448142 by Sun Yat-sen University, with a registry enrolment figure of 50 participants, started 2026-03-15 and due to reach its primary completion in 2027-09-01. Interventions recorded: Low-dose radiotherapy; Pucotenlimab; CAPEOX/XELOX. Conditions listed: Colorectal Cancer (CRC). Primary outcome: Complete Response Rate (CR). Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Pucotenlimab, IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares IMRT / IGRT (modern external beam), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.